Video: The impact of Brexit on the British advanced therapeutic research sector

We held a short interview with Matthew Durdy (Chief Business Officer at Cell & Gene Therapy Catapult) at our Phacilitate Leaders Forum to get his thoughts.

Phacilitate’s inaugural Investment for Advanced Therapies will provide Pharma and Biotech companies with the perfect platform to stand out from the crowd and show why their products and technology are worth backing. At the same time, it will provide Investors with the tools they need to be able to make informed decisions about what is happening in the space and where the greatest opportunities lie.

Investment for Advanced Therapies will run alongside ISCT, ensuring access to the most active pharma and biotech companies that will already be in London. With an expected audience of over 180, including at least 50 investors, there’s something for everyone.

Find out more: